Red Cell Distribution Width (RDW) as a Prognostic Marker in Systemic Diseases: A Mini Review

Red Cell Distribution Width (RDW), a routinely available parameter in complete blood counts, reflects the variability in red blood cell size. Originally used to differentiate types of anemia, RDW has emerged as a valuable prognostic marker across a wide range of systemic diseases. Elevated RDW levels have been associated with increased morbidity and mortality in cardiovascular diseases, chronic kidney disease, diabetes, liver disorders, infections, inflammatory conditions, and malignancies. The rise in RDW may reflect underlying inflammation, oxidative stress, nutritional deficiencies, bone marrow dysfunction, or impaired erythropoiesis, all of which are common features in systemic illnesses. As a readily available, non-invasive, and cost-effective biomarker, RDW offers significant clinical utility in risk stratification, disease monitoring, and outcome prediction. Its prognostic value has been particularly noted in heart failure, sepsis, chronic obstructive pulmonary disease, and various cancers, where it correlates with disease severity and adverse outcomes. Despite its potential, the exact pathophysiological mechanisms linking RDW to systemic disease progression remain incompletely understood, warranting further research. This mini review summarizes current evidence on the prognostic significance of RDW in systemic conditions, explores possible underlying mechanisms, and highlights its role in clinical decision-making. Given its simplicity and accessibility, RDW has the potential to be integrated into routine clinical assessment to enhance early detection of complications and guide therapeutic strategies. However, standardization in interpretation and further validation in diverse populations are needed to fully establish RDW as a reliable prognostic tool in systemic diseases.